Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
35.70
-0.08 (-0.22%)
At close: Feb 27, 2026, 4:00 PM EST
35.75
+0.05 (0.14%)
After-hours: Feb 27, 2026, 7:52 PM EST

Corcept Therapeutics Stock Forecast

Stock Price Forecast

The 5 analysts that cover Corcept Therapeutics stock have a consensus rating of "Buy" and an average price target of $105.2, which forecasts a 194.68% increase in the stock price over the next year. The lowest target is $60 and the highest is $150.

Price Target: $105.2 (+194.68%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$60$105.2$100$150
Change+68.07%+194.68%+180.11%+320.17%

Analyst Ratings

The average analyst rating for Corcept Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingSep '25Oct '25Nov '25Dec '25Jan '26Feb '26
Strong Buy333333
Buy111111
Hold001222
Sell000000
Strong Sell000000
Total445666

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$67$60
Strong BuyMaintains$67$60+68.07%Feb 25, 2026
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$105$67
Strong BuyMaintains$105$67+87.68%Feb 20, 2026
Canaccord Genuity
Canaccord Genuity
Strong Buy
Maintains
$99$100
Strong BuyMaintains$99$100+180.11%Jan 23, 2026
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$90$105
Strong BuyMaintains$90$105+194.12%Jan 23, 2026
Canaccord Genuity
Canaccord Genuity
Strong Buy
Maintains
$140$99
Strong BuyMaintains$140$99+177.31%Jan 2, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
994.62M
from 761.41M
Increased by 30.63%
Revenue Next Year
1.31B
from 994.62M
Increased by 31.61%
EPS This Year
0.62
from 0.82
Decreased by -24.54%
EPS Next Year
3.14
from 0.62
Increased by 406.87%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
365.98M401.86M482.38M675.04M761.41M994.62M1.31B
Revenue Growth
3.42%9.80%20.04%39.94%12.79%30.63%31.61%
EPS
0.890.870.941.230.820.623.14
EPS Growth
4.71%-2.25%8.05%30.85%-33.33%-24.54%406.87%
Forward PE
-----57.6911.38
No. Analysts
-----86
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20262027202820292030
High1.1B1.8B
Avg994.6M1.3B
Low826.1M934.1M

Revenue Growth

Revenue Growth20262027202820292030
High
49.9%
77.8%
Avg
30.6%
31.6%
Low
8.5%
-6.1%

EPS Forecast

EPS20262027202820292030
High1.504.20
Avg0.623.14
Low-0.912.46

EPS Growth

EPS Growth20262027202820292030
High
83.1%
578.7%
Avg
-24.5%
406.9%
Low-
297.5%
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.